

Supplementary materials

For those statements for which there was no consensus in the first round of voting, the statement was reworded and resubmitted. Below are the original texts submitted and the subsequent amendments until the consensus of the voters was obtained.

Figure 1. Statement 4





Figure 2. Statement 5

Statement 5- First round

Monitoring of ARV therapy today should include markers of immune-activation such as pro-inflammatory cytokines.


Statement 5- First round



Statement 5- Second round

Monitoring ARV therapy today cannot be done without the use of markers of immune-activation, such as pro-inflammatory cytokines.

Statement 5- Second round



Statement 5- Third round

The monitoring of ARV therapy today cannot be separated from the use of immune-activation markers in daily clinical practice.

Statement 5- Third round




Figure 3. Statement 8






Figure 4. Statement 14



Statement 14- Second round



Statement 14- Third round

The weight gain observed with modern drug regimens (TAF, integrase inhibitors), in people with BMI <30 kg/m² and in absence of metabolic syndrome and other risk factors, has so far shown no correlation with increased cardiovascular risk. A longer follow-up will provide more precise indications.

Statement 14- Third round

